Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Pfizer Inc. Latest News & Job Openings
#1
Information 
Headquartered in New York (USA), Pfizer Inc. a global giant in Pharmaceutical industry holds one of the most experienced portfolio (founded in 1849) in therapeutic drugs and services across the world. With an aim to address the diverse healthcare medical needs of the patients around the world, Pfizer has kept expanding it's R&D base and hence the product lines round the clock. From Lipitor, Idamycin, Cardura to Viagra etc almost every product of Pfizer has dominated the market post-launch.

Here is a brief overview of the recent developments at Pfizer Inc, with the information on latest job opportunities in this esteemed pharmaceutical firm.
  • Results of Zoetis Inc. Exchange Offer Declared
Pfizer Inc., the owner of common stocks of Zoetis Inc. had offered a share exchange offer, wherein the Zoetis common stock shares could be exchanged with Pfizer common stock shares. The exchange offer had expired at 00:00 hrs, NY City time, June 21, 2013. And, the results of the exchange offer were declared on Thursday, June 27, 2013. As per the declaration 0.9898 shares of Zoetis common stock were exchanged for every 1 share of Pfizer common stock.

For Details on the declaration Click here
  • TEVA and Sun Pharmaceuticals Settle for $2.15 billion penalty for Infringement of Pfizer's Protonix Patent
After a long legal battle of nearly 10 years, Pfizer (and Pfizer’s subsidiary Wyeth and Takeda) have successfully obtained the settlement of $2.15 billion from TEVA Pharmaceuticals and Sun Pharmaceutical Industries, Limited for the infringement of the patent for their blockbuster medicine Protonix, by launching the generics before the expiry of the patent in January 2011. As a part of the settlement, Teva will pay $1.6 billion and Sun will pay $550 million to Pfizer and Takeda.

For Details on the story, Click here
  • FDA Accepts Pfizer's Application for Reviewing and Expanding the XELJANZ Labeling
Pfizer announced on June 21, 2013 that FDA has accepted to review it's application for expanding the labeling of XELJANZ (tofacitinib citrate), used for severely active Rheumatoid Arthritis to include it's efficacy in inhibition of Progression of Structural Damage too. XELJANZ is the first FDA approved medicine in the class of Janus kinase (JAK) inhibitors, and is effective in treating the patients unresponsive or intolerant to Methotrexate (MTX).

For Details, Click here

Following are the recent job openings at Pfizer in United States:

Note down the JOB ID and Apply here

A. Quality Assurance:
[Image: pfizer_quality.png]

B. Research & Development
[Image: rnd_pfizer.png]

Keep an eye on this thread for further updates.


Thanks for Reading!
Sunil Nagpal
MS(Research) Scholar, IIT Delhi (Alumnus)
Advisor for the Biotech Students portal (BiotechStudents.com)
Computational Researcher in BioSciences at a leading MNC


Suggested Reads:
Top Biotech Companies | Top places to work
Indian Biotech Companies and Job Openings
Aiming a PhD in Top Grad School? | These are the Important Points to Consider
Careers in Biotechnology | A list of various Options
Biotechnology Competitive Exams in India
#2

Ireland this year is going to see a lot of development in the pharmaceutical sector. None other the pharma giant Pfizer is stepping in with huge investments. Currently as per announcements $30 million is being invested in the Ringaskiddy site in Cork and $100 million is being invested in the Grange Castle site in Dublin. Investment in Grange Castle is expected to bring double productivity to current process of rheumatoid arthritis which in turn will bring a lot of profile. Expansion of site is also expected to build proper space for mammalian biotechnology processes. This is going to bring many products in Ireland pharma pipeline.
Consturction has been launched and the facility will be operational in 2015, followed by design, operations and process validation. Further audits can be expected by US-FDA, Health Canada, EMEA etc, for approving the site for production of international quality drugs. Whereas, Ringaskiddy site investment is aimed at developing speciality anti-cancer drugs, some of them are novel and will be newest addition to the pharma plans of Pfizer.

As per news agencies the latest investment is supported by IDA Ireland, the country's investment agency, and the headed by chief executive Barry O'Leary said that the Ringaskiddy site was Pfizer’s first production house in Ireland with a history of 45 years and "it is fantastic to see the work at that site evolve into high-tech manufacturing". Pfizer in last four decades has invested more than $7 billion in Ireland since opening its first site. Currenty the pharmaceutical giant employs 3,200 people at six sites in the country.

What to look for as outcomes?
#Around new 250 jobs are expected to be announced, so keep an eye for jobs in Ireland. All those who are graduating in recent years have really good chance to get absorbed.
#Cheaper and high quality anti-cancer, arthrities drugs, etc.
#A big leap for biotechnology industry in Ireland.
Kalpana Samant
Bioprocess Engineer & Freelancer
  

Possibly Related Threads...
Thread
Author
  /  
Last Post
Replies: 3
Views: 9,801
02-18-2017, 05:29 PM
Last PostAbdul
Replies: 12
Views: 252,155
12-21-2016, 01:37 AM
Last Postniharuddin
Replies: 0
Views: 1,560
03-31-2016, 09:06 PM
Last PostHEL Group
Replies: 0
Views: 8,652
07-25-2015, 04:16 AM
Last Postgmshim
Replies: 1
Views: 7,107
03-26-2015, 04:12 PM
Last Postjuston33



Users browsing this thread:
1 Guest(s)

Pfizer Inc. Latest News & Job Openings00